EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of cancer"
DOI: 10.1016/j.ejca.2016.11.012
Abstract: OBJECTIVES Cancerous inhibitor of protein phosphatase 2A (CIP2A) has emerged as a therapeutic determinant mediating the anti-cancer effects of several new agents. We investigated the efficacy and mechanism of TD52, an erlotinib derivative with minimal… read more here.
Keywords: erlotinib derivative; td52; cip2a; elk1 cip2a ... See more keywords